Park Ha Biological Technology (BYAH) investor relations material

Company overview and business model

• Operates a private skincare label with direct product sales and franchise alliances, focusing on solutions for problematic skin through the “Park Ha” brand in China.

• Revenue streams include product sales and franchise fees, with a network of 39 franchisees as of April 30, 2025, and three directly operated stores.

• Franchise model allows flexibility for franchisees in inventory management and provides comprehensive training and marketing support.

• R&D center focuses on skincare for sensitive skin, with a product line of nearly 70 items across 10 series, leveraging small molecule peptide technology.

• Digital marketing and O2O (online-to-offline) strategies are used to drive customer engagement and sales.

Financial performance and metrics

• Total revenue for the six months ended April 30, 2025, was $1,239,197, up from $852,928 in the prior year period; product sales accounted for 33% and franchise fees 67%.

• Fiscal year ended October 31, 2024, revenue was $2,381,851, down from $2,459,102 in 2023; net income for FY2024 was $478,561, down from $852,042 in FY2023.

• Recorded a net loss of $19,835,994 for the six months ended April 30, 2025, compared to net income of $48,900 in the prior year period.

• As of April 30, 2025, net tangible book value per share was $0.14; post-offering, adjusted net tangible book value is estimated at $0.12 per share, with $0.02 dilution to new investors.

Use of proceeds and capital allocation

• Estimated net proceeds of $2.517 million (assuming full subscription) will be used primarily for expansion of directly operated stores.

• Management retains flexibility to reallocate proceeds as business conditions evolve; unused funds will be invested in short-term, interest-bearing instruments.